FindTrial
Sign In

Multi-center clinical study on third-generation sequencing as a first-line thalassemia gene detection technology

Multi-center clinical study of single molecule sequencing as a first-line thalassemia gene detection technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124736
Enrollment
Unknown
Registered
2026-05-17
Start date
2026-05-18
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassemia

Interventions

Gold Standard:Gene diagnosis
Index test:single-molecule real-time,SMRT

Sponsors

Guangdong Provincial Maternal and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Couples who have undergone prenatal examination in sampled medical institutions, and at least one of them is positive in blood routine test and at least one of them is positive in hemoglobin electrophoresis test.

Exclusion criteria

Exclusion criteria: 1. Any reason preventing the acquisition of valid and sufficient samples; 2. Samples that have undergone blood transfusion for various reasons within the past six months; 3. Other circumstances deemed unsuitable for participation in this clinical study by the researchers.

Design outcomes

Primary

MeasureTime frame
Gene diagnosis result;—

Countries

China

Contacts

Public ContactYin Aihua

Guangdong Provincial Maternal and Child Health Hospital

yinaiwa@126.com+86 20 39151547

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026